vs
Side-by-side financial comparison of MYRIAD GENETICS INC (MYGN) and QuidelOrtho Corp (QDEL). Click either name above to swap in a different company.
QuidelOrtho Corp is the larger business by last-quarter revenue ($699.9M vs $209.8M, roughly 3.3× MYRIAD GENETICS INC). On growth, MYRIAD GENETICS INC posted the faster year-over-year revenue change (-0.4% vs -3.7%). Over the past eight quarters, MYRIAD GENETICS INC's revenue compounded faster (1.9% CAGR vs -2.9%).
Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life, identify a pati...
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
MYGN vs QDEL — Head-to-Head
Income Statement — Q4 2025 vs Q3 2026
| Metric | | |
|---|---|---|
| Revenue | $209.8M | $699.9M |
| Net Profit | — | $-733.0M |
| Gross Margin | 70.0% | — |
| Operating Margin | -2.7% | -100.7% |
| Net Margin | — | -104.7% |
| Revenue YoY | -0.4% | -3.7% |
| Net Profit YoY | — | -3583.4% |
| EPS (diluted) | $-0.09 | $-10.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $209.8M | — | ||
| Q3 25 | $205.7M | $699.9M | ||
| Q2 25 | $213.1M | $613.9M | ||
| Q1 25 | $195.9M | $692.8M | ||
| Q4 24 | $210.6M | $707.8M | ||
| Q3 24 | $213.3M | $727.1M | ||
| Q2 24 | $211.5M | $637.0M | ||
| Q1 24 | $202.2M | $711.0M |
| Q4 25 | — | — | ||
| Q3 25 | $-27.4M | $-733.0M | ||
| Q2 25 | $-330.5M | $-255.4M | ||
| Q1 25 | $-100.0K | $-12.7M | ||
| Q4 24 | — | $-178.4M | ||
| Q3 24 | $-22.1M | $-19.9M | ||
| Q2 24 | $-36.7M | $-147.7M | ||
| Q1 24 | $-26.0M | $-1.7B |
| Q4 25 | 70.0% | — | ||
| Q3 25 | 69.9% | — | ||
| Q2 25 | 71.2% | — | ||
| Q1 25 | 68.5% | — | ||
| Q4 24 | 71.7% | — | ||
| Q3 24 | 70.2% | — | ||
| Q2 24 | 69.6% | — | ||
| Q1 24 | 68.1% | — |
| Q4 25 | -2.7% | — | ||
| Q3 25 | -11.3% | -100.7% | ||
| Q2 25 | -154.5% | -29.4% | ||
| Q1 25 | -14.8% | 4.7% | ||
| Q4 24 | -18.6% | -14.2% | ||
| Q3 24 | -9.4% | 2.1% | ||
| Q2 24 | -17.3% | -18.4% | ||
| Q1 24 | -13.8% | -247.3% |
| Q4 25 | — | — | ||
| Q3 25 | -13.3% | -104.7% | ||
| Q2 25 | -155.1% | -41.6% | ||
| Q1 25 | -0.1% | -1.8% | ||
| Q4 24 | — | -25.2% | ||
| Q3 24 | -10.4% | -2.7% | ||
| Q2 24 | -17.4% | -23.2% | ||
| Q1 24 | -12.9% | -239.9% |
| Q4 25 | $-0.09 | — | ||
| Q3 25 | $-0.29 | $-10.78 | ||
| Q2 25 | $-3.57 | $-3.77 | ||
| Q1 25 | $0.00 | $-0.19 | ||
| Q4 24 | $-0.47 | $-2.54 | ||
| Q3 24 | $-0.24 | $-0.30 | ||
| Q2 24 | $-0.41 | $-2.20 | ||
| Q1 24 | $-0.29 | $-25.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $149.6M | $98.1M |
| Total DebtLower is stronger | $119.9M | $2.5B |
| Stockholders' EquityBook value | $368.0M | $2.0B |
| Total Assets | $706.6M | $5.7B |
| Debt / EquityLower = less leverage | 0.33× | 1.23× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $149.6M | — | ||
| Q3 25 | $145.4M | $98.1M | ||
| Q2 25 | $74.4M | $151.7M | ||
| Q1 25 | $91.8M | $127.1M | ||
| Q4 24 | $102.4M | $98.3M | ||
| Q3 24 | $99.9M | $143.7M | ||
| Q2 24 | $97.3M | $107.0M | ||
| Q1 24 | $104.3M | $78.5M |
| Q4 25 | $119.9M | — | ||
| Q3 25 | $119.5M | $2.5B | ||
| Q2 25 | — | $2.1B | ||
| Q1 25 | — | $2.1B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B | ||
| Q1 24 | — | $2.2B |
| Q4 25 | $368.0M | — | ||
| Q3 25 | $372.8M | $2.0B | ||
| Q2 25 | $388.1M | $2.8B | ||
| Q1 25 | $704.9M | $3.0B | ||
| Q4 24 | $701.1M | $3.0B | ||
| Q3 24 | $731.7M | $3.2B | ||
| Q2 24 | $740.5M | $3.2B | ||
| Q1 24 | $760.0M | $3.3B |
| Q4 25 | $706.6M | — | ||
| Q3 25 | $728.1M | $5.7B | ||
| Q2 25 | $677.3M | $6.4B | ||
| Q1 25 | $1.0B | $6.5B | ||
| Q4 24 | $1.0B | $6.4B | ||
| Q3 24 | $1.1B | $6.8B | ||
| Q2 24 | $1.1B | $6.7B | ||
| Q1 24 | $1.1B | $6.7B |
| Q4 25 | 0.33× | — | ||
| Q3 25 | 0.32× | 1.23× | ||
| Q2 25 | — | 0.74× | ||
| Q1 25 | — | 0.70× | ||
| Q4 24 | — | 0.72× | ||
| Q3 24 | — | 0.68× | ||
| Q2 24 | — | 0.70× | ||
| Q1 24 | — | 0.68× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $10.6M | $-45.5M |
| Free Cash FlowOCF − Capex | — | $-94.7M |
| FCF MarginFCF / Revenue | — | -13.5% |
| Capex IntensityCapex / Revenue | — | 7.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-153.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $10.6M | — | ||
| Q3 25 | $21.1M | $-45.5M | ||
| Q2 25 | $-13.6M | $-46.8M | ||
| Q1 25 | $-16.3M | $65.6M | ||
| Q4 24 | $6.6M | $63.7M | ||
| Q3 24 | $700.0K | $117.9M | ||
| Q2 24 | $2.6M | $-97.9M | ||
| Q1 24 | $-18.6M | $-700.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | $-94.7M | ||
| Q2 25 | — | $-84.3M | ||
| Q1 25 | — | $9.4M | ||
| Q4 24 | — | $16.5M | ||
| Q3 24 | — | $71.4M | ||
| Q2 24 | — | $-133.2M | ||
| Q1 24 | — | $-66.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | -13.5% | ||
| Q2 25 | — | -13.7% | ||
| Q1 25 | — | 1.4% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 9.8% | ||
| Q2 24 | — | -20.9% | ||
| Q1 24 | — | -9.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | 7.0% | ||
| Q2 25 | — | 6.1% | ||
| Q1 25 | — | 8.1% | ||
| Q4 24 | — | 6.7% | ||
| Q3 24 | — | 6.4% | ||
| Q2 24 | — | 5.5% | ||
| Q1 24 | — | 9.3% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MYGN
Segment breakdown not available.
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
